Christopher J. Hasenberg Inc Takes Position in Eli Lilly and Company (NYSE:LLY)

Christopher J. Hasenberg Inc acquired a new position in Eli Lilly and Company (NYSE:LLY) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 870 shares of the company’s stock, valued at approximately $507,000. Eli Lilly and Company accounts for 0.3% of Christopher J. Hasenberg Inc’s investment portfolio, making the stock its 17th largest position.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Lipe & Dalton purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth approximately $26,000. Thompson Investment Management Inc. purchased a new stake in Eli Lilly and Company in the 3rd quarter worth approximately $27,000. Tidemark LLC acquired a new stake in shares of Eli Lilly and Company during the 4th quarter valued at $29,000. Legacy Financial Group LLC acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at $35,000. Finally, Optiver Holding B.V. purchased a new position in shares of Eli Lilly and Company during the 3rd quarter valued at $36,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

NYSE LLY traded up $3.82 during midday trading on Monday, hitting $737.33. The company had a trading volume of 2,726,536 shares, compared to its average volume of 3,017,770. The firm has a fifty day simple moving average of $760.89 and a two-hundred day simple moving average of $668.00. Eli Lilly and Company has a fifty-two week low of $392.26 and a fifty-two week high of $800.78. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The stock has a market cap of $700.58 billion, a price-to-earnings ratio of 127.13, a P/E/G ratio of 1.60 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter last year, the company earned $2.09 earnings per share. The firm’s revenue was up 28.1% on a year-over-year basis. Equities analysts forecast that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.13% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on LLY shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $815.00 price objective on shares of Eli Lilly and Company in a report on Monday, April 15th. BMO Capital Markets raised their price target on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Truist Financial reissued a “buy” rating and issued a $850.00 price target on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Bank of America raised their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $728.05.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.